Loading...
NPI 1386692333 · Nampa, ID · Neurology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lawrence Green is a neurology physician provider located in Nampa, Idaho. This profile covers 8 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Lawrence Green |
| Address | 16060 Idaho Center Blvd |
| City | Nampa |
| State | ID |
| ZIP | 83687 |
| Taxonomy | Neurology Physician |
| NPI Enumerated | May 4, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $594.2K |
| Medicaid | $21.7K |
Practice revenue is highly concentrated in a single high-cost biologic administration: J2350 (Injection, ocrelizumab, 1 mg) accounts for $580.8K in Medicare revenue, 13.2K claims at $44 avg paid/claim, and represents 96.9% of this provider's total Medicare revenue. The vendor precomputation shows the top 3 Medicare codes account for 99.3% of Medicare revenue, signaling the practice is essentially driven by ocrelizumab infusions for Medicare patients rather than a broad mix of neurology services.
Medicare vs Medicaid scale is lopsided: total Medicare revenue is $594.2K while total Medicaid revenue is $21.7K, so Medicare dominates the payer mix economically and likely drives the provider’s operational focus. Medicaid activity is minimal in dollar terms relative to Medicare, indicating the provider functions effectively as a Medicare-focused revenue center.
Medicaid billing is concentrated in office visits: 99213 represents the entirety of recorded Medicaid revenue ($21.9K, 625 claims, $35 avg paid/claim) and is responsible for 100.0% of this provider's Medicaid revenue. The in-state rank for that code is #363 of 669 providers (46th percentile; typical, unremarkable volume), suggesting routine outpatient follow-up care for Medicaid patients rather than specialty infusion services.
Competitive standing for the Medicare top drug is modest nationally: J2350 ranks #51 of 105 providers nationally (52th percentile; typical, unremarkable volume), which indicates the provider has a measurable but not dominant presence among peers administering ocrelizumab. Despite the large revenue share from J2350, the rank and the provided label characterize volume as typical rather than an outlier.
Office visit coding shows different roles across payers: the same code 99213 appears in Medicare (209 claims, $11.9K revenue, ranked #93607 of 457151 nationally, 79th percentile; typical, unremarkable volume) and dominates Medicaid billing, indicating that routine evaluation-and-management visits form the bulk of non-drug encounters. The dual appearance of 99213 with different volumes and pay rates ($57 avg paid/claim in Medicare vs $35 in Medicaid) reflects payer-driven variation in encounter mix and reimbursement.
Ancillary and infusion-related codes appear but contribute negligible Medicare revenue beyond the top drug: 96413 (chemotherapy administration) accounts for $2.2K (24 claims, $91 avg paid/claim) and 95910 (nerve conduction studies) accounts for $2.1K (20 claims, $106 avg paid/claim), and the top-3 Medicare codes collectively make up 99.3% of Medicare revenue. Both 96413 (rank #6748 of 7514, 9th percentile; typical, unremarkable volume) and 95910 (rank #1797 of 3046, 38th percentile; typical, unremarkable volume) are labeled as typical volumes, indicating these services are ancillary to the core infusion business rather than primary revenue drivers.
Provider tenure is long-standing: the NPI was enumerated on 2006-05-04 (~20 years ago), which suggests sustained practice presence and credentialing stability in the market. That tenure, paired with very focused Medicare drug revenue, suggests an established clinical program centered on infusion/biologic administration rather than a recently launched service line.
Operational implication: the code mix and revenue concentration imply a neurology practice structured around infusion delivery of a high-cost MS biologic (J2350) for Medicare beneficiaries, with Medicaid encounters primarily limited to office E/M visits (99213). Payers and network managers should view this provider as a specialized infusion/biologic administrator with routine outpatient follow-up care rather than a broad-spectrum neurology clinic.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | 13,200 | $40 | $580.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 210 | $60 | $11.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 20 | $90 | $2.2K |
| 95910 | In this procedure, the provider performs seven or eight nerve conduction studies, a diagnostic test to evaluate the function, especially the electrical conduction ability of the motor and sensory… | 20 | $110 | $2.1K |
| 96116 | A physician or other qualified healthcare professional performs a face–to–face assessment of a patient’s thinking, reasoning, and judgment. Report this code for the first hour of face–to–face… | 20 | $70 | $1.4K |
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 40 | $20 | $700 |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 10 | $10 | $150 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 30 | $1 | $120 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 8 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 630 | $40 | $21.9K |
How this provider's Medicaid billing volume and revenue compare to other Idaho providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Idaho median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 363 | 670 | 740 | $40 | $193.6K |
Other providers in the same ZIP code as Lawrence Green, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.